Which companies overlap with Gruppo Italiano Terapie Innovative nei Linfomi's portfolio?

Top competitors by shared drug class: Amgen, Assistance Publique - Hôpitaux de Paris, Beijing Friendship Hospital, Centre Hospitalier Universitaire de Saint Etienne, Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gruppo-italiano-terapie-innovative-nei-linfomi.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Gruppo Italiano Terapie Innovative nei Linfomi — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gruppo Italiano Terapie Innovative nei Linfomi pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Rituximab-HDS	Rituximab-HDS	phase 3	Monoclonal antibody (anti-CD20)	CD20	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Amgen · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Beijing Friendship Hospital · 1 shared drug class
Centre Hospitalier Universitaire de Saint Etienne · 1 shared drug class
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH · 1 shared drug class
Dr. Reddy's Laboratories Limited · 1 shared drug class
Hoffmann-La Roche · 1 shared drug class
Laida Cuevas Palomares · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Gruppo Italiano Terapie Innovative nei Linfomi:

Cite this brief

Drug Landscape (2026). Gruppo Italiano Terapie Innovative nei Linfomi — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gruppo-italiano-terapie-innovative-nei-linfomi. Accessed 2026-05-18.